152 related articles for article (PubMed ID: 7691767)
1. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
2. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
[TBL] [Abstract][Full Text] [Related]
3. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
4. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
6. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
[TBL] [Abstract][Full Text] [Related]
8. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
[TBL] [Abstract][Full Text] [Related]
9. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
Epstein C; Lynch T; Shefner J; Wen P; Maxted D; Braman V; Ariniello P; Coral F; Ritz J
Int J Cancer Suppl; 1994; 8():57-9. PubMed ID: 7515030
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
12. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.
O'Connor R; Liu C; Ferris CA; Guild BC; Teicher BA; Corvi C; Liu Y; Arceci RJ; Goldmacher VS; Lambert JM; Blättler WA
Blood; 1995 Dec; 86(11):4286-94. PubMed ID: 7492789
[TBL] [Abstract][Full Text] [Related]
13. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
Grossbard ML; Fidias P; Kinsella J; O'Toole J; Lambert JM; Blattler WA; Esseltine D; Braman G; Nadler LM; Anderson KC
Br J Haematol; 1998 Jul; 102(2):509-15. PubMed ID: 9695966
[TBL] [Abstract][Full Text] [Related]
14. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.
Liu C; Lambert JM; Teicher BA; Blättler WA; O'Connor R
Blood; 1996 May; 87(9):3892-8. PubMed ID: 8611717
[TBL] [Abstract][Full Text] [Related]
15. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
16. Toxicologic evaluations of an immunotoxin, H65-RTA.
Kung AH; Cavagnaro JA; Makin A; White MA; Kong KN
Fundam Appl Toxicol; 1995 Jun; 26(1):75-84. PubMed ID: 7657064
[TBL] [Abstract][Full Text] [Related]
17. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
[TBL] [Abstract][Full Text] [Related]
20. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Tsimberidou AM; Giles FJ; Kantarjian HM; Keating MJ; O'Brien SM
Leuk Lymphoma; 2003 Oct; 44(10):1719-25. PubMed ID: 14692524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
